



9200

Sp 1806

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Entire application : Griffith, et al.
Serial No. : 07/730,452 Art Unit: 1806
Filed : July 15, 1991
Attorney Docket No. : IPC-025C
For : ALLERGENIC PROTEINS AND PEPTIDES
FROM JAPANESE CEDAR POLLEN

#12
J. Griffith
3-1-93

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231 on 2/2/93.

By: Darlene Vanstone
Darlene A. Vanstone
Registration No. 35,729
Attorney for Applicants

RECEIVED

FEB 24 1993

INFORMATION DISCLOSURE STATEMENT

GROUP 180

Honorable Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

It is desired to cite for the record in this application the enclosed patents listed on the attached copy of PTO Form 1449.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

Respectfully submitted,

By: Darlene Vanstone 2/2/93


Darlene A. Vanstone, Reg. No. 35,729
Attorney for Applicants

IMMULOGIC PHARMACEUTICAL
CORPORATION

P 30018 02/22/93 07730452

09-0087 Lincoln Street
Waltham, MA 02154

200.00CH



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Griffith, et al.
Serial No. : 07/730,452 Art Unit: 1806
Filed : July 15, 1991
Attorney Docket No. : IPC-025C
For : ALLERGENIC PROTEINS AND PEPTIDES
FROM JAPANESE CEDAR POLLEN

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231 on 2/2/93.

By

Darlene A. Vanstone
Registration No. 35,729
Attorney for Applicants

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

RECEIVED

FEB 24 1993

GROUP 180

Sir:

Transmitted herewith is:

- [X] a Supplemental Information Disclosure Statement
- [X] a 1 page PTO 1449 citing 4 references
- [X] also transmitted is The references cited in PTO 1449 Form

1. ☐ This Supplemental Information Disclosure Statement if filed before the later of:

- a. three months from the filing date of this national application;
- b. three months from the date of entry of the national stage as forth in 37 CFR 1.491 in an international application, or;
- c. the mailing date of a first Office Action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. ☒ This Information Disclosure Statement is filed after the events noted in paragraph 1, but before either:

- a. a final action under 37 CFR 1.113, or
- b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c) also enclosed is:

- ☒ a fee under 37 CFR 1.17(p) in the amount of \$200.00; or
- ☐ a certification as stated below.

3. ☐ This Information Disclosure Statement is filed before the payment of the issue fee, but after either:

- a. a final action under 37 CFR 1.113, or
- b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d) also enclosed is:

- a. a certification, as stated below;
- b. a Petition requesting consideration of the Information Disclosure Statement, and
- c. the Petition fee set forth in 37 CFR 1.17(i)(I) in the amount of \$130.00.

Certification

The undersigned also states:

- ☐ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.


The fees indicated above are:

TOTAL FEES:

- ☒ Please charge Deposit Account No. 09-0087 in the amount of \$200.00
- ☐ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment of any fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 09-0087.

This form is being **submitted in triplicate** for accounting purposes.

Respectfully submitted,



Darlene A. Vanstone
Attorney for Applicants
Registration No. 35,729
Date: 2/2/93

ImmuLogic Pharmaceutical Corporation
Patent Department
610 Lincoln Street
Waltham, MA 02154
Telephone: 617-466-6000